title: Novel therapy for type 1 diabetes: autologous hematopoietic stem cell transplantation.
abstract: Type 1 diabetes is characterized pathologically by autoimmune insulitis-related islet β-cell destruction. Although intensive insulin therapy for patients with type 1 diabetes can correct hyperglycemia, this therapy does not prevent all diabetes-related complications. Recent studies have shown that autologous hematopoietic stem cell transplantation (HSCT) is a promising new approach for the treatment of type 1 diabetes by reconstitution of immunotolerance and preservation of islet β-cell function. Herein we discuss the therapeutic efficacy and potential mechanisms underlying the action of HSCT and other perspectives in the clinical management of type 1 diabetes.
authors.affiliation: Division of Endocrinology, The Affiliated Drum Tower Hospital of Nanjing University, Nanjing, China.
authors.forename: Lirong
authors.initials: L
authors.lastname: Li
authors.forename: Weiqiong
authors.initials: W
authors.lastname: Gu
authors.forename: Dalong
authors.initials: D
authors.lastname: Zhu
mesh_terms: D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007108:Immune Tolerance; D050417:Insulin-Secreting Cells / Q000502:physiology / Q000637:transplantation; D007515:Islets of Langerhans / Q000503:physiopathology; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous